111 related articles for article (PubMed ID: 19389858)
1. The role of p-glycoprotein in limiting brain penetration of the peripherally acting anticholinergic overactive bladder drug trospium chloride.
Geyer J; Gavrilova O; Petzinger E
Drug Metab Dispos; 2009 Jul; 37(7):1371-4. PubMed ID: 19389858
[TBL] [Abstract][Full Text] [Related]
2. Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
Bundgaard C; Jensen CJ; Garmer M
Drug Metab Dispos; 2012 Mar; 40(3):461-6. PubMed ID: 22112383
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of alfentanil in P-glycoprotein-competent and P-glycoprotein-deficient mice: P-glycoprotein efflux alters alfentanil brain disposition and antinociception.
Kalvass JC; Olson ER; Pollack GM
Drug Metab Dispos; 2007 Mar; 35(3):455-9. PubMed ID: 17178769
[TBL] [Abstract][Full Text] [Related]
4. P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion.
Tahara H; Kusuhara H; Fuse E; Sugiyama Y
Drug Metab Dispos; 2005 Jul; 33(7):963-8. PubMed ID: 15821041
[TBL] [Abstract][Full Text] [Related]
5. P-glycoprotein (ABCB1) transports the primary active tamoxifen metabolites endoxifen and 4-hydroxytamoxifen and restricts their brain penetration.
Iusuf D; Teunissen SF; Wagenaar E; Rosing H; Beijnen JH; Schinkel AH
J Pharmacol Exp Ther; 2011 Jun; 337(3):710-7. PubMed ID: 21378205
[TBL] [Abstract][Full Text] [Related]
6. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.
Schinkel AH; Wagenaar E; Mol CA; van Deemter L
J Clin Invest; 1996 Jun; 97(11):2517-24. PubMed ID: 8647944
[TBL] [Abstract][Full Text] [Related]
7. Trospium chloride treatment of overactive bladder.
Biastre K; Burnakis T
Ann Pharmacother; 2009 Feb; 43(2):283-95. PubMed ID: 19193592
[TBL] [Abstract][Full Text] [Related]
8. Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography.
Hendrikse NH; Schinkel AH; de Vries EG; Fluks E; Van der Graaf WT; Willemsen AT; Vaalburg W; Franssen EJ
Br J Pharmacol; 1998 Aug; 124(7):1413-8. PubMed ID: 9723952
[TBL] [Abstract][Full Text] [Related]
9. P-glycoprotein efflux at the blood-brain barrier mediates differences in brain disposition and pharmacodynamics between two structurally related neurokinin-1 receptor antagonists.
Smith BJ; Doran AC; McLean S; Tingley FD; O'Neill BT; Kajiji SM
J Pharmacol Exp Ther; 2001 Sep; 298(3):1252-9. PubMed ID: 11504828
[TBL] [Abstract][Full Text] [Related]
10. Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux.
Dai H; Marbach P; Lemaire M; Hayes M; Elmquist WF
J Pharmacol Exp Ther; 2003 Mar; 304(3):1085-92. PubMed ID: 12604685
[TBL] [Abstract][Full Text] [Related]
11. Blonanserin, a novel atypical antipsychotic agent not actively transported as substrate by P-glycoprotein.
Inoue T; Osada K; Tagawa M; Ogawa Y; Haga T; Sogame Y; Hashizume T; Watanabe T; Taguchi A; Katsumata T; Yabuki M; Yamaguchi N
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Oct; 39(1):156-62. PubMed ID: 22691713
[TBL] [Abstract][Full Text] [Related]
12. Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics.
Bexten M; Oswald S; Grube M; Jia J; Graf T; Zimmermann U; Rodewald K; Zolk O; Schwantes U; Siegmund W; Keiser M
Mol Pharm; 2015 Jan; 12(1):171-8. PubMed ID: 25466967
[TBL] [Abstract][Full Text] [Related]
13. Regional differences in capillary density, perfusion rate, and P-glycoprotein activity: a quantitative analysis of regional drug exposure in the brain.
Zhao R; Pollack GM
Biochem Pharmacol; 2009 Oct; 78(8):1052-9. PubMed ID: 19523457
[TBL] [Abstract][Full Text] [Related]
14. Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics.
Lagas JS; Vlaming ML; van Tellingen O; Wagenaar E; Jansen RS; Rosing H; Beijnen JH; Schinkel AH
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6125-32. PubMed ID: 17062689
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of acute and sub-chronic aripiprazole in P-glycoprotein deficient mice.
Kirschbaum KM; Uhr M; Holthoewer D; Namendorf C; Pietrzik C; Hiemke C; Schmitt U
Neuropharmacology; 2010 Nov; 59(6):474-9. PubMed ID: 20599439
[TBL] [Abstract][Full Text] [Related]
16. Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder.
Staskin D; Kay G; Tannenbaum C; Goldman HB; Bhashi K; Ling J; Oefelein MG
Int J Clin Pract; 2010 Aug; 64(9):1294-300. PubMed ID: 20561092
[TBL] [Abstract][Full Text] [Related]
17. P-glycoprotein reduces the ability of amitriptyline metabolites to cross the blood brain barrier in mice after a 10-day administration of amitriptyline.
Grauer MT; Uhr M
J Psychopharmacol; 2004 Mar; 18(1):66-74. PubMed ID: 15107187
[TBL] [Abstract][Full Text] [Related]
18. Altered disposition and antinociception of [D-penicillamine(2,5)] enkephalin in mdr1a-gene-deficient mice.
Chen C; Pollack GM
J Pharmacol Exp Ther; 1998 Nov; 287(2):545-52. PubMed ID: 9808679
[TBL] [Abstract][Full Text] [Related]
19. Trospium chloride for the treatment of overactive bladder with urge incontinence.
Singh-Franco D; Machado C; Tuteja S; Zapantis A
Clin Ther; 2005 May; 27(5):511-30. PubMed ID: 15978301
[TBL] [Abstract][Full Text] [Related]
20. Trospium chloride: Distinct among other anticholinergic agents available for the treatment of overactive bladder.
Staskin DR
Urol Clin North Am; 2006 Nov; 33(4):465-73, viii. PubMed ID: 17011382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
